Ruth Hulbert 💜

Well, that's a wrap folks! completely overwhelmed by the outpouring of love & appreciation. Words don't seem enough, but thank you from the bottom of my heart to everyone who has supported & stuck by me through the trials, tribulations & triumphs. So grateful 🙏 ❤️

@SarahHa88622902 @EKHUFT Thank you so much - it has been an absolute privilege ❤️

We will miss you so much @ruthulbert - a brilliant nurse and leader, we are incredibly proud of all you have achieved- thank you for all you have given to nursing and to East Kent- enjoy exciting next steps #proudCNMO @EKHUFT

There's still time to register to join us on the 14 January for a webinar for potential host and partner organisations of the new Health and Care Professionals Internships scheme! The webinar will include: 🔵 an overview of the scheme 🔵 the aims and expectations of the delivery of the programme 🔵a live Q&A Register now: eu01web.zoom.us/webinar/regist…

Thanks to @BBCBreakfast who this morning highlighted the need for more foster carers. They featured two @diagramaukkids foster carers and the poignant Christmas single ‘Welcome Home’ which they wrote and recorded with their choir to promote foster care. youtu.be/IynLhyWGBXk?si…

As the end of 2024 draws near, our research teams reflect on all they have achieved this year in @EKHUFT - soooooo much to be proud of! 💜👏🌟 @EKHUFT_Research @EKHUFT_EKCRC @ResearchHarvey @KandCHResearch @EKHUFT_RI_QEQM

Don’t forget to take care of yourself! ❤️

“It’s fantastic news that elacestrant has been approved for use on the NHS in England, providing for the first time, a targeted treatment specifically for certain people with ER-positive, HER2-negative incurable secondary breast cancer with an ESR1 mutation.” @clairerowney

Great turn out for our Christmas (and my final) team meeting today... Lots of surprises & emotions so feeling a little overwhelmed, but very loved 🥹❤️🎄 @EKHUFT_Research @ResearchHarvey @EKHUFT_RI_QEQM @EKHUFT_EKCRC @KandCHResearch #fabulousstuff #bestteam

Excellent work! And such fabulous results for our patients ❤️ @EKHUFT

@Pegg3Claire Thank you ❤️ It's been a joy to work with such committed & passionate people. I know the group will continue to thrive going forward under your fabulous leadership 😊

So yesterday we celebrated one of our legendary Workforce Development members who is heading for retirement in the new year! So grateful to @ruthulbert for all her guidance, support and dedication to the WFDSG over numerous years!

@EKHUFT_RI_QEQM @UKRoxTrial Well done all! 👏

Recruitment completed for the UK ROX trial. 75 recruited! Big well done to everyone at QEQM ITU. 👏🙌 @UKRoxTrial

So proud too @Emma29946729! ❤️

@NIHRtakepart Thank you! 😊

@ruthulbert Hi Ruth, apologies for the inconvenience, here is the correct link: nihr.ac.uk/starting-out-g…

Being involved is not the same as taking part in a study to test a new treatment. Public involvement is about being a member of the team that works together to design and run the study. Read our Starting Out Guide to learn more about getting involved: nihr.ac.uk/documents/Star…

So excited to see this launched! 😄 This will really help to support our ambition to increase commercial research activity in @EKHUFT ⬇️

As of today, 80,000 people have signed up to Join Dementia Research. That's the equivalent of a sold out concert at the London Stadium! Thank you to all of our volunteers. If you haven't already, you can register online today at joindementiaresearch.nihr.ac.uk

We're excited to announce we will be hosting the #ColoPrevent trial at Kent & Canterbury Hospital! 🍇🍇#Resveratrol #clinicaltrial #clinicalresearch #bowelcancer theguardian.com/science/2024/n…

Great to see this, and especially that our very own Senior Research Nurse, Liz, is one of the successful participants 😊 Congratulations all! 👏 @EKHUFT_EKCRC

Fabulous! Well done all! 👏 🥳🌟

📢 Exciting news for people with myeloma! A new life-changing drug, teclistamab, has now been approved for 4th-line use on the NHS in England and Wales. This breakthrough brings new hope to those exhausting other treatment options. 1/5